Incyte Corp. to Acquire Escient Pharmaceuticals for $750M

Wilmington, DE, April 23, 2024 (RTTNews) -- Incyte Corp. (INCY) is buying Escient Pharmaceuticals and its assets for $750 million, plus any cash left over when the deal closes. This acquisition needs approval under the Hart-Scott-Rodino Act and some standard conditions. If everything goes as planned, the deal could be finished by the third quarter of 2024.

Read full article here.